

**Amendments to the Claims:**

This listing of the claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1-8 Cancelled

9 (Currently Amended). A method for ~~treating a neurological disease or disorder~~ inducing myelination and remyelination of neurons and protecting neurons from pathological insults, comprising administering to a patient in need thereof an effective amount of interleukin-6 receptor - interleukin-6 (IL6RIL6 chimera), thereby resulting in the induction of myelination or remyelination of neurons or the protection of neurons from pathological insults.

10 (Currently Amended). A ~~The~~ method of claim 9, for protecting neurons from pathological insults, wherein the pathological insult is one resulting from ~~for treating multiple sclerosis (MS), Alzheimer's disease, Parkinson's disease or amyotrophic lateral sclerosis (ALS) comprising administering to a patient in need thereof an effective amount of IL6RIL6 chimera.~~

11 (Currently Amended). The method of claim 9, for inducing myelination and remyelination of neurons, wherein the patient in need is one suffering from ~~neurological disease or disorder treated is~~ traumatic nerve degeneration, or a

Appln. No. 09/980,823  
Amdt. dated July 23, 2004  
Reply to Office action of February 23, 2004

demyelinating disease of the central nervous system (CNS) or peripheral nervous system (PNS), ~~and/or a neurodegenerative disease.~~

12 (Currently Amended). The method of claim 11, wherein the patient in need ~~demyelinating disease treated is~~ one suffering from multiple sclerosis (MS).

13 (Canceled).

14 (Previously Presented). A method in accordance with claim 9, wherein said IL6RIL6 chimera is administered together with a pharmaceutically acceptable carrier.

15 (Previously Presented). A method in accordance with claim 10, wherein said IL6RIL6 chimera is administered together with a pharmaceutically acceptable carrier.